Mural Oncology (NASDAQ: MURA, $1.12, Market Capitalization $19.30 million), a clinical-stage oncology company focused on discovering and developing immunotherapies, provided an update on the Phase 3 ...
Mural Oncology announced updates regarding its late-stage trials for nemvaleukin alfa, with interim data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and in Q2 2025 ...
Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. And while targeted ...
Treatment-free survival after immunotherapy discontinuation in advanced melanoma: A systematic review and meta-analysis of real-world studies. This is an ASCO Meeting Abstract from the 2024 ASCO ...
DUBLIN, Jan. 17, 2023 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS) today announced that nemvaleukin alfa (nemvaleukin), the company's investigational, novel engineered interleukin-2 (IL-2) ...
Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study. A targeted panel of actionable high ...
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback